Insulet (NSDQ:PODD) is issuing a voluntary medical device correction for all of the smartphone-like Personal Diabetes Managers that came with its next-gen Omnipod Dash insulin management system, the company announced today. During its ongoing quality management process, Insulet officials discovered that the PDMs on rare occasions will suggest an inaccurate bolus amount based on a blood […]
Insulet
Insulet Q3 earnings beat The Street despite bottom-line slide
Insulet (NSDQ:PODD) shares are rising today on third-quarter results that topped the consensus forecast, despite a dip in profits. The Acton, Mass.–based company posted profits of $852,000, or 1¢ per share, on sales of $192.1 million for the three months ended Sept. 30, for a 48.6% bottom-line slide on sales growth of 27.1%. Adjusted to exclude […]
Insulet wins FDA nod for Omnipod with Novo Nordisk’s Fiasp insulin
Insulet (NSDQ:PODD) said last week that it won FDA clearance for the use of Novo Nordisk‘s (NYSE:NVO) Fiasp insulin with the Omnipod insulin management platform. Acton, Mass.-based Insulet said it completed extensive testing to ensure that Fiasp is safe and usable with the Omnipod and Omnipod Dash systems. It’s the first insulin pump in the U.S. […]
FDA clears Insulet’s OmniPod Dash as insulin pump alternative
Insulet (NSDQ:PODD) said today that it won FDA clearance to market its Omnipod Dash alternate controller-enabled (ACE) infusion pump as an integrated insulin pump. The Acton, Mass.-based company received FDA 510(k) clearance for the Omnipod Dash in June 2018 and launched the device earlier this year. The latest indication states that the pump can reliably and […]
Insulet prices $700m offering
Insulet (NSDQ:PODD) today priced a private placement of $700 million in convertible senior notes due 2026. The offering is slated to close on Sept. 6. The Acton, Mass.-based company said in a press release it also gave initial purchasers an option to buy up to an additional $100 million in notes. Insulet reported that it expects […]
Insulet touts full market launch of mobile apps for Omnipod Dash
Insulet (NSDQ:PODD) touted the full market launch of the Omnipod Display and Omnipod View apps for people using the company’s Omnipod Dash system. The Display app enables users to display data from their Personal Diabetes Manager device onto their smartphones. The View app gives caregivers and family members the option to remotely monitor Omnipod Dash […]
Omnipod Dash sales drive Insulet Q2 results
Insulet (NSDQ:PODD) reported second-quarter results yesterday that missed the consensus forecast on Wall Street, but raised its outlook for the rest of the year. The Acton, Mass.-based diabetes tech company reported profits of $1.4 million or $0.02 per share, on sales of $177.1 million for the three months ended June 30, 2019, for a bottom-line […]
Inside Insulet’s pivotal year with CEO Shacey Petrovic
It’s been a busy year at Insulet (NSDQ:PODD). The diabetes tech company welcomed a new CEO, launched its first new product in six years and officially opened its $200 million global headquarters – all in the first half of 2019. That’s all the result of years of rapid growth for Insulet, chief executive Shacey Petrovic said in a keynote […]
ADA 2019: Hybrid closed-loop devices take center stage
The American Diabetes Association’s 79th Scientific Sessions is a five-day conference where researchers and healthcare professionals share the latest in diabetes research. More than 180 sessions and over 2,000 research presentations took place during the meeting on June 7-11 in San Francisco. During the meeting, diabetes experts shared data and research from clinical trials. Here […]
Insulet posts Street-beating Q1 earnings
Shares in Insulet (NSDQ:PODD) are steady in after-hours trading after the diabetes-focused device maker posted first quarter earnings that topped Wall Street expectations. The Acton, Mass.-based company posted profits of approximately $4.4 million, or 7¢ per share, on sales of approximately $159.6 million for the three months ended March 31, seeing a swing from the red […]